These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3381494)

  • 1. [Use of nitrosourea derivatives in the treatment of patients with Hodgkin's disease with lesions of the central nervous system].
    Gershanovich ML; Arkhipov AI; Vilenskiĭ BS
    Vopr Onkol; 1988; 34(5):542-9. PubMed ID: 3381494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrosourea derivatives for the treatment of Hodgkin's disease involving the central nervous system: a study of 23 cases.
    Gershanovich ML; Arkhipov AI; Vilensky BS
    Bull Cancer; 1990; 77(8):821-8. PubMed ID: 2207371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
    Filatova LV; Gershanovich ML
    Vopr Onkol; 2008; 54(5):643-52. PubMed ID: 19069483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined chemotherapy of lymphogranulomatosis].
    Raevskiĭ IG; Vermel' AE; Korman NP; Lebedev VN; Gerase VV
    Vopr Onkol; 1977; 23(6):15-20. PubMed ID: 919402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)].
    Illés A; Bányai A; Szegedi G
    Orv Hetil; 1994 May; 135(22):1187-90. PubMed ID: 8015814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.
    Cervantes F; Reverter JC; Montserrat E; Rozman C
    Cancer Treat Rep; 1986 May; 70(5):665-7. PubMed ID: 3708614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
    Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
    Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of lomustine, teniposide, procarbazine and prednisone (LTPP) in the treatment of terminal-state Hodgkin's disease].
    Robak T; Krykowski E; Olszańska-Skorek T; Urbańska-Ryś H; Dmochowska M; Chojnowski K
    Pol Tyg Lek; 1986 Feb; 41(7):199-202. PubMed ID: 3714560
    [No Abstract]   [Full Text] [Related]  

  • 17. [Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease].
    Kumagai K; Takagi T; Sakai C; Wakatsuki S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):499-501. PubMed ID: 8678506
    [No Abstract]   [Full Text] [Related]  

  • 18. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
    Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA
    Cancer Treat Rep; 1987 May; 71(5):475-8. PubMed ID: 3567972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of age on therapeutic response and survival in advanced Hodgkin's disease.
    Peterson BA; Pajak TF; Cooper MR; Nissen NI; Glidewell OJ; Holland JF; Bloomfield CD; Gottlieb AJ
    Cancer Treat Rep; 1982 Apr; 66(4):889-98. PubMed ID: 7042088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment outcome of advanced Hodgkin's disease based on using an alternating program ChLVPP (chlorambucil, vinblastine, procarbazine, prednisone) and ABV (doxorubicin, bleomycin, vinblastine)].
    Komarnicki M; Balcerzak A; Górski P; Pawlak L; Hansz J
    Acta Haematol Pol; 1994; 25(4):363-8. PubMed ID: 7531381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.